Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Basit Öğe Kaydı
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorAraz, Murat
dc.date.accessioned2026-01-24T12:31:24Z
dc.date.available2026-01-24T12:31:24Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.doi10.1056/NEJMc2306786
dc.identifier.endpage478
dc.identifier.issn0028-4793
dc.identifier.issn1533-4406
dc.identifier.issue5
dc.identifier.pmid37530832
dc.identifier.scopus2-s2.0-85166143198
dc.identifier.scopusqualityQ1
dc.identifier.startpage476
dc.identifier.urihttps://doi.org/10.1056/NEJMc2306786
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5838
dc.identifier.volume389
dc.identifier.wosWOS:001086308700018
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMassachusetts Medical Soc
dc.relation.ispartofNew England Journal of Medicine
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.titleCabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
dc.typeLetter

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu